Understanding and targeting cancer persister cells

This project aims to develop tools for studying cancer persister cells using single-cell lineage tracing to enhance understanding and treatment of therapy-resistant tumors.

Subsidie
€ 1.728.750
2024

Projectdetails

Introduction

Despite tremendous progress in cancer therapy, many patients still succumb to the disease following an initial successful response to treatment. In addition to the long-appreciated contribution of genetically mutated cells to disease recurrence, persister cells, a rare subpopulation of cells that evade therapy in the absence of any known resistance-mediating mutation, have recently emerged as orthogonal drivers of therapy failure.

Challenges in Understanding Persister Cells

While there has been much progress in targeting genetic resistance, the paucity of molecular tools that can capture persister traits, as well as the lack of a robust methodological framework for their study, have significantly hampered our understanding and ability to target persister cells.

Opportunities for Research

Nevertheless, recent breakthroughs in molecular profiling techniques, as well as growing access to human residual disease clinical samples, now provide the opportunity to uncover the molecular underpinnings of this crucial cellular state.

Project Proposal

In this project, I propose to combine state-of-the-art single-cell lineage tracing techniques with functional approaches to:

  1. Identify the determinants that control the ability of persister cells to escape therapy-induced senescence.
  2. Elucidate the cellular processes that govern the duration of persister drug-induced arrest.
  3. Investigate how epigenetic memory shapes persisters’ response to subsequent cycles of therapy.

Goals of CancerPersisters

CancerPersisters will establish the tools that are needed in order to study key persister traits and further our understanding of this important cancer phenotype.

Potential Impact

Successful completion of this project may instruct the development of new classes of cancer drugs that can resensitize patients to subsequent cycles of therapy by erasing cellular memory and increase progression-free survival by modulating the duration of drug-induced arrest.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.728.750
Totale projectbegroting€ 1.728.750

Tijdlijn

Startdatum1-8-2024
Einddatum30-9-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • TEL AVIV UNIVERSITYpenvoerder

Land(en)

Israel

Vergelijkbare projecten binnen European Research Council

ERC Consolid...

Cancer cell plasticity on targeted therapy

This project aims to develop innovative cancer therapies by analyzing tumor heterogeneity and targeting drug-tolerant persister cells to prevent resistance and improve patient outcomes.

€ 2.000.000
ERC Consolid...

Dynamics of Adaptation and Resistance in Cancer: MApping and conTrolling Transcriptional and Epigenetic Recurrence

This project aims to uncover the mechanisms of drug resistance in colorectal cancer through innovative models and computational methods, ultimately improving treatment strategies and patient outcomes.

€ 1.995.582
ERC Consolid...

Deciphering non-genetic determinants and targetability of cancer cell plasticity.

This project aims to reverse cancer cell plasticity in pediatric tumors using advanced genomic techniques to develop new therapeutic strategies for effective treatment.

€ 2.000.000
ERC Consolid...

What doesn’t kill you: primed and adaptive mechanisms of treatment resistance in ovarian cancer

This project aims to develop a novel methodology to identify and target pre-existing resistant cell states in ovarian cancer, enhancing therapy effectiveness through sequential drug combinations.

€ 1.999.754
ERC Starting...

Applying novel single-cell multiomics to elucidate leukaemia cell plasticity in resistance to targeted therapy

This project aims to develop a single-cell multiomics method to understand epigenetic resistance mechanisms in AML, enhancing treatment strategies against drug resistance.

€ 1.882.440

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

Functional chemical reprogramming of cancer cells to induce antitumor immunity

The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.

€ 2.966.695
EIC Transition

Next-Generation Drug Discovery Platform for Targeting Cancer Stem Cell Pathways

Develop a drug discovery platform using patient-derived organoids and machine learning to target stem cell signaling pathways in colorectal cancer, aiming to improve treatment outcomes.

€ 2.433.125